WHAT'S NEW IN GI PHARMACOLOGY COURSE
Friday, October 25, 2019 | 1:45 pm - 5:15 pm | Stars at Night Ballroom - B2
Course Directors: Brooks D. Cash, MD, FACP, and William D. Chey, MD, FACP

COURSE DESCRIPTION
Attend ACG's What's New in GI Pharmacology Course for an intensive review of key GI pharmacology, including comparisons and contrasts between conventional and emerging pharmacological treatment options. This course will consist of lectures and Q & A sessions on such topics as eosinophilic esophagitis, gastroparesis, primary and salvage therapies for H. pylori, peptic ulcer bleeding, SIBO and bloating, medical therapies for Crohn’s Disease, autoimmune hepatitis, and how and when to use neuromodulators for functional upper and lower GI syndromes.

The course is designed primarily for physicians in GI/hepatology, as well as physician assistants, nurse practitioners, and other advanced practice healthcare professionals interested in the latest information on state-of-the-art treatment of these illnesses.

ACCREDITATION / CME / MOC
The American College of Gastroenterology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Gastroenterology designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

COURSE AGENDA
1:45 pm Welcome and Introductions
Brooks D. Cash, MD, FACP, and William D. Chey, MD, FACP

1:50 pm New Concepts in the Treatment of Eosinophilic Esophagitis
Evan S. Dellon, MD, MPH, FACP
Review recent updates in the epidemiology, nomenclature, diagnostic processes, and management of eosinophilic esophagitis.

2:10 pm Jump-Starting Gastroparesis
Michael Camilleri, MD, MACG
Discuss the diagnosis of gastroparesis in a variety of clinical scenarios, and review current and emerging pharmacologic options for the management of gastroparesis symptoms.

2:30 pm Primary and Salvage Therapies for H. pylori
William D. Chey, MD, FACP
Describe the recently-updated ACG guidelines for the management of H. pylori-related disease and review current therapeutic approaches to H. pylori eradication.

2:50 pm Gastroprotection and the Renaissance of Peptic Ulcer Bleeding: Who Needs It and Who Doesn’t
John R. Saltzman, MD, FACP
Identify the evidence for and against the use of gastrointestinal prophylaxis for peptic ulcer disease in patients with systemic disease associated with increased risk of gastrointestinal complications.

3:10 pm Q & A
3:25 pm Break

3:40 pm Contemporary Approach to SIBO and Bloating
Linda Anh B. Nguyen, MD
Discuss current and emerging diagnostic and treatment options for small intestinal bacterial overgrowth and bloating.

4:00 pm Medical Therapies for Crohn’s Disease: What to Start With and When to Change
Mollie D. Long, MD, MPH, FACP
Describe the evidence for when to employ different medical therapies available for Crohn’s disease and review algorithms for altering medical management when necessary.

4:20 pm Autoimmune Hepatitis: When to Move Beyond Steroids
Steven L. Flamm, MD, FACP
Review the diagnostic varieties for AIH and provide recommendations for appropriate medical approaches for the various AIH forms.

4:40 pm How and When to Use Neuromodulators for Functional Upper and Lower GI Syndromes
Brooks D. Cash, MD, FACP
Explain the rationale, evidence, and outcomes associated with neuromodulators for patients with functional dyspepsia, non-cardiac chest pain, and irritable bowel syndrome.

5:00 pm Q & A
5:15 pm What’s New in GI Pharmacology Course Adjourns
FRIDAY COURSES
Friday, October 25, 2019

FACULTY LISTING AND DISCLOSURE INFORMATION

The American College of Gastroenterology (ACG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ACG, as an ACCME accredited provider, ensures balance, independence, objectivity, and scientific rigor in all of its directly and jointly provided education activities. All who are in a position to control the content of an education activity (including their spouse or partner) are required to disclose to ACG all relevant financial relationships in any amount occurring in the past 12 months with any commercial interest that may create a conflict of interest related to the subject matter of an education activity. Safeguards against commercial bias have been put in place by ACG. Anyone who refuses to disclose relevant financial relationships will be disqualified. ACG ensures any conflicts of interest are resolved before the educational activity occurs and discloses all relevant financial relationships to the learners prior to the beginning of an education activity.

ACG staff involved with this activity have nothing to disclose. Faculty have noted the following relationships related to their GI Pharmacology Course presentations.

COURSE DIRECTORS

Brooks D. Cash, MD, FACG
Professor of Medicine, University of Texas Health Science Center at Houston/McGovern Medical School, Houston, TX
Consultant: Allergan, Salix, Shire, Synergy
Speakers Bureau: Allergan, Portola, Salix, Synergy

William D. Chey, MD, FACG
Nostrant Professor of Gastroenterology & Nutrition, University of Michigan; Director, GI Physiology Lab, Michigan Medicine, Ann Arbor, MI
Advisory Committee/Board Member: GI Health Foundation, My Total Health, Rome Foundation
Consultant: Allergan, Biomerica, IM Health, Ironwood, Nestlé, Prometheus, QOL Medical, Ritter, Valeant
Employee: My Total Health
Grant/Research Support: Ardeleyx, Nestlé Health Sciences, QOL Medical, Vibrant Stockholder/Ownership Interest (excluding diversified mutual funds): True Self

EVAN S. DELLON, MD, MPH, FACG
Professor of Medicine and Associate Professor of Epidemiology, Center for Esophageal Diseases and Swallowing, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
Consultant: Adare, Alvio, Allakos, Banner, Calypso, Celgene/Receptos, Enunmeral, EsoCao, GlaxoSmithKline, Gossamer Bio, Receptos, Regeneron, Robarts, Shire
Grant/Research Support: Allakos, AstraZeneca, Banner, Celgene/Receptos, GlaxoSmithKline, Holoclar, Meritage, Miraca Life Sciences, Receptos, Regeneron, Shire

STEVEN L. FLAMM, MD, FACG
Professor of Medicine and Surgery, Northwestern Feinberg School of Medicine, Chicago, IL
Dr. Flamm has indicated no relevant financial relationships.

MILLIE D. LONG, MD, MPH, FACG
Associate Professor of Medicine, University of North Carolina, Center for Gastrointestinal Biology and Disease, Chapel Hill, NC
Advisory Committee/Board Member: AbbVie, Janssen, Pfizer, Prometheus, Takeda, UCB, Inc.
Consultant: AbbVie, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, Theravance, UCB, Inc.
Grant/Research Support: Pfizer, Takeda, Theravance

LINDA ANH B. NGUYEN, MD
Clinical Associate Professor; Clinic Director, Digestive Health Center; Director, Neurogastroenterology & Motility, Stanford University, Redwood City, CA
Consultant: Allergan, Ironwood, Neurogastrx, Salix
Grant/Research Support: Allergan
Speakers Bureau: Allergan, Ironwood, Salix
Speakers Bureau (spouse): Allergan, Ironwood, Salix

JOHN R. SALTZMAN, MD, FACG
Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Advisory Committee/Board Member: Iterative Scopes

INVESTIGATIONAL USE DISCLOSURES

ACG’s disclosure policy maintains that if any unapproved or off-label use of a product is to be referenced in a CME program, the faculty member is required to disclose that the product is either investigational or it is not labeled for the usage being discussed. The following faculty members have indicated they may reference an off-label use in their Pharmacology Course presentation(s).

Dr. Camilleri – relamorelin, eluxadoline, TAK-954
Dr. Dellon – There are no FDA-approved medications for EoE, so everything discussed is experimental or off-label.
Dr. Nguyen – buspirone

PEER REVIEW SUBCOMMITTEE MEMBERS

To resolve identified conflicts of interest, the educational content was peer reviewed by the Course Director or a member of the ACG Educational Affairs Peer Review Subcommittee.

SCOTT L. GABBARD, MD (Chair), Cleveland, OH
Dr. Gabbard has indicated no relevant financial relationships.

STEVEN L. CARPENTER, MD, FACG, SAVANNAH, GA
Dr. Carpenter has indicated no relevant financial relationships.

JOHN O. CLARKE, MD, STANFORD, CA
Dr. Clarke has indicated no relevant financial relationships.

STEVEN L. FLAMM, MD, FACG, CHICAGO, IL
Dr. Flamm has indicated no relevant financial relationships.

AARON S. GOLDBERG, MD, PHOENIX, AZ
Dr. Goldberg has indicated no relevant financial relationships.

EDITH Y. HO, MD, MS, FACG, CLEVELAND, OH
Dr. Ho has indicated no relevant financial relationships.

SHIVANGI T. KOTHARI, MD, FACG, ROCHELLE, NY
Dr. Flamm has indicated no relevant financial relationships.

RENEE L. YOUNG, MD, FACG, OMAHA, NE
Dr. Young has indicated no relevant financial relationships.

FACULTY

MICHAEL CAMILLERI, MD, MACG
Professor of Medicine, Pharmacology, and Physiology, Mayo Clinic College of Medicine and Science, Rochester, MN
Advisory Committee/Board Member: Allergan, consulting re: relamorelin with fee to my employer, Mayo Clinic, Takeda
Grant/Research Support: Allergan, Rhythm, Takeda: research grant to study TAK954

BROOKS D. CASH, MD, FACG
Professor of Medicine, University of Texas Health Science Center at Houston/McGovern Medical School, Houston, TX
Dr. Cash has indicated no relevant financial relationships.

WILLIAM D. CHEY, MD, FACG
Nostrant Professor of Gastroenterology & Nutrition, University of Michigan; Director, GI Physiology Lab, Michigan Medicine, Ann Arbor, MI
Consultant: Biomerica
Grant/Research Support: Biomerica

FOLLOW ON SOCIAL MEDIA #ACG2019 OR CHECK OUT THE ACG BLOG: ACGBLOG.ORG

45